Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum's therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/19/16 | $55,000,000 | Series A |
Third Rock Ventures | undisclosed |
